श्रेणी: News

Cabaletta Bio (NASDAQ:CABA) è stata fondata nel 2017.  La società ha sede a Philadelphia, PA, USA. L’azienda è focalizzata sullo sviluppo di terapie a base di cellule T per il trattamento di malattie autoimmuni. L’azienda collabora con diverse istituzioni professionali come l’Università della Pennsylvania, il Children’s Hospital of Philadelphia e la società di biotecnologie IASO Bio.

Cabaletta Bio ha ricevuto l’autorizzazione della FDA (Food and Drug Administration) per l’applicazione dell’innovativo IND CABA-201, utilizzato per trattare l’autoimmunità attraverso recettori chimici attivi completamente umani. L’azienda prevede inoltre di avviare un secondo studio clinico su CABA-201, che esaminerà lo stato degli autoanticorpi generati.

Il presidente di Cabaletta Bio, Gwendolyn Binder, ha recentemente dichiarato tramite un comunicato stampa: “Negli ultimi due anni abbiamo avuto una collaborazione di successo con WuXi ATU (un’azienda biofarmaceutica che si occupa di ricerca molecolare, sviluppo, produzione e ricerca biologica, test di terapia genica di prodotti medici) per produrre nuove terapie cellulari in modo conforme alle GMP. “Sulla base di questa collaborazione, abbiamo deciso di espandere la nostra partnership per includere WuXi ATU come produttore dei nostri programmi clinici CABA-201 (completamente umano, chimico, recettore dell’antigene)”.

L’azienda ha generato un fatturato totale di 15,890 miliardi di dollari nel secondo trimestre del 2023, con un aumento del 16,83% rispetto all’anno precedente. Le attività totali dell’azienda sono cresciute del 57,85% a 184,637 miliardi di dollari. Il patrimonio netto della società è aumentato del 66,6%, raggiungendo un valore di 174,141 miliardi di dollari. Questi fatti hanno attirato l’attenzione di società di investimento multinazionali e di investitori privati per l’acquisto di azioni di Cabaletta Bio (NASDAQ:CABA) in particolare, per le quali prevedono una forte crescita del prezzo delle azioni, per le quali è stato fissato un prezzo obiettivo medio di 29,80 dollari per azione per un orizzonte di investimento a breve e medio termine.

Microsoft Corporation has launched a major investment in the state of Georgia, in Floyd County, on Huffaker Road in Rome.  This investment will exceed $1 billion and will include the construction of a data center to support the Azure platform. “This is a tremendous economic opportunity for our community that will have positive impacts for decades to come,” said Jimmy Byars, Chairman of the Rome Floyd County Development Authority. The site itself is 347 acres in size. The company will also create 150 senior management jobs at the Georgia data center with this investment. This project is expected to take about three years to complete.

Microsoft Azure (“Azure”) is Microsoft Inc’s global technology infrastructure, which consists of two key components – physical infrastructure and interconnecting network components. This technology infrastructure consists of more than 200 physical data centers, organized into regions and connected by one of the largest interconnected technology networks in the world.

The high EPS (earnings per share) growth rate for Microsoft (cash value per share) was 21.3%, so investors should focus on the projected growth in Microsoft Corporation (NASDAQ-MSFT)’s share price.  Multinational investment firms expect earnings per share for (NASDAQ-MSFT) to grow 13.2% this year, outperforming the IT industry average of 11.9%. Microsoft also received the highest EPS growth score from analysts at investment magazine Zacks.

The company also pays regular quarterly dividends to its shareholders. Currently, the dividend yield is 0.86% p.a. The actual dividend amount was approved by the AGM at $0.75 per share. The company also currently has a known date for the use of the stock’s dividend payment (NASDAQ-MSFT), the so-called Ex-Dividend-Date), which has been set for November 15, 2023. The company has set the actual dividend payment date (Pay-Date) for January 25, 2024. According to analysts at brokerage firms and financial strategists at investment banks, the stock price can be expected to rise in the short to medium term investment horizon. The average target price for the short- to medium-term investment horizon has been set at $408.83 per share.

On October 30, 2023, Apple Inc. will announce new product innovations, such as the next-generation iMacs and the unveiling of a next-generation silicon chip, through a press conference “frighteningly fast” for journalists. Not long ago, the company unveiled the new iPhone 15 last month. Apple also introduced the new Apple Pencil electronic pencil. More president of worldwide product marketing for Apple Inc. Bob Borchers said : “Apple Pencil has revolutionized note-taking, sketching and illustrating, unleashing endless possibilities for productivity and creativity. Combined with the versatility of iPad, the new Apple Pencil unlocks another great way to experience the magic of digital handwriting, annotation, document mark-up and more.”

The company also recently released its third quarter results for the year, in which service revenue reached a new all-time high and the number of Apple apps downloaded reached an all-time high. The company reported third-quarter revenue of $81.8 billion, down 1% year-over-year, and earnings per diluted share of $1.26, up 5% year-over-year. These facts have attracted the attention of banking institutions and multinational investment corporations for buying the stock. Apple Inc (AAPL:NASDAQ) also pays regular quarterly attractive dividends to its shareholders. The dividend yield is currently 0.55% p.a. The actual dividend amount has been approved by the company’s general meeting of shareholders at $0.24 per share. The average target price has been set for the short to medium term investment horizon at USD 204.80 per share.

NVIDIA Corp (NASDAQ-NVDA) is an American technology company headquartered in Santa Clara, California, USA and was founded in April 1993. The company’s CEO and President is Jensen Huang. The company designs graphics processing units (GPUs) for the gaming and professional markets, as well as system-on-chips (SoCs) for the mobile and automotive markets. Since 2014, NVIDIA Corp (NASDAQ-NVDA) has expanded its focus into the professional gaming visualization, data center, and artificial intelligence industries.

Few names have garnered as much attention in 2023 as NVIDIA Corp (NASDAQ-NVDA). Known for its cutting-edge semiconductor technology, this giant has seen its stock rise more than 130% year-over-year, making it a headline-grabbing title in investment circles. Much of this meteoric rise can be attributed to the robust production and sales performance of Nvidia’s H100 GPU (micro-architecture GPU), which debuted in the third quarter of fiscal year 2023. However, as the saying goes, what goes up must also come down, and Nvidia stock is no exception. NVIDIA recently reported second quarter earnings results that came in above the expectations of global analysts. The company’s revenue was up 101% year-over-year to $13.51 billion. The company also posted record year-over-year growth in data center revenue with a 171% increase to $10.32 billion.

NVIDIA Founder and CEO Jensen Huang said, “A new era of computing has begun. Companies around the world are transitioning to generative AI, where NVIDIA GPUs connect to their Mellanox networking technologies, which run on our CUDA AI software suite to form the computing infrastructure for generative AI. During the second quarter of the fiscal year, NVIDIA returned $3.38 billion to shareholders in the form of 7.5 million shares of common stock and a $3.28 billion cash dividend. At the end of the second quarter, NVIDIA Corp (NASDAQ-NVDA) had $3.95 billion remaining under its share repurchase authorization. On Aug. 21, 2023, the company’s board of directors authorized an additional $25.00 billion in share repurchases without expiration. NVIDIA Corp (NASDAQ-NVDA) plans to continue to repurchase shares this fiscal year.

NVIDIA Corp (NASDAQ-NVDA) also pays regular quarterly dividends to its shareholders. The dividend yield is currently 0.035% per annum and the actual dividend amount has been approved by the company’s general meeting of shareholders at $0.04 per share. The average target price for the short to medium term investment horizon has been set at $645.65 per share.

Advanced Micro Devices, Inc. (AMD:NASDAQ) announced via press release that it is launching new processors for the data center. These new processors are designated the AMD EPYC 8004 Series. These new processors provide up to twice the performance with low power consumption, which could save users thousands of dollars in electricity costs over the next five years. With this move, the company is fulfilling its stated guidance after the release of its second quarter 2023 financial results that the new products it will introduce in the second half of this year will help the company grow revenue at double the rate of its sales and earnings, which could reach $20 billion.

AMD’s data center CPUs are used in the cloud service provider’s (CSP) servers. AMD has a performance and price advantage over competitor Intel that allows AMD to continue to gain market share. Advanced Micro Devices, Inc. (AMD:NASDAQ) will also launch a new MI300 graphics processing unit (GPU) chip later this year to compete with dominant market leader NVIDIA by making this chipset more attractively priced. AMD has already partnered with Microsoft and Meta, while Amazon sells AMD chips on its e-store. According to banking institutions and multinational investment corporations, the stock price can be expected to rise in the short to medium term investment horizon, where the average target price has been set at $137.57 per share. 

The company has seen strong sales growth and investor interest at Amazon Prima day , held annually on July 11-12. The first half of Prime Day 2023 was Amazon’s biggest sales day ever. All the Prime Day stats are out and they are records. The two-day event saw more than 375 million items sold worldwide with savings of more than $2.5 billion. Amazon claims the first day of the event was Amazon’s biggest sales day in their history. The event was also the biggest Prime Day ever for independent retailers, with some small businesses seeing an 18-fold increase in average daily sales. TikTok played a big role in the success of Prime Day, with more than 400 million video views with the hashtags #primeday, #primeday2023 and #amazonprimeday2023. The number of Prime Day-related views has skyrocketed over the past few years, nearly doubling year-over-year. Google was another who briefly flirted with the idea of competing with Amazon. For a while, Google Shopping had a section called “Buy with Google” that allowed shoppers to browse and buy products directly on Google. While Google Shopping is still alive, Google has reportedly killed off its Buy with Google section, with all results now pointing to merchants’ own websites, preventing the notion of Google as a direct competitor to Amazon.

The company recently released financial results for the second quarter of 2023.

– Amazon’s second quarter was very successful. In the fourth quarter, the company expects even higher revenue growth. The company will focus on cutting costs and investing in new areas such as advertising due to the economic difficulties of high order packaging costs.

– Amazon’s second-quarter earnings topped analysts’ expectations, with revenue rising 11% to $134.4 billion compared with the same quarter a year earlier.

– AWS revenue rose 12% to $22.1 billion, accounting for 70% of Amazon’s operating profit.

– Amazon’s advertising business also grew, with revenues of $10.7 billion in the latest quarter.

– Q3 revenue is estimated to be around USD 138bn to USD 143bn, which corresponds to a growth of 9% to 13%.

These facts have attracted the attention of multinational banking corporations and private equity investors to buy shares of Amazon.com, Inc (NASDAQ-AMZN). The average target price for the short- to medium-term investment horizon has been set at $175.90 per share.

Pfizer Inc. (NYSE-PFE) announced via press release that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (COMIRNATY 2023-2024 formulation) for individuals 12 years of age and older, granting emergency use authorization for individuals 6 months of age through 11 years of age for the monovalent COVID-19 vaccine adapted to the Omicron XBB virus mutation.1 .5. This season’s vaccine is indicated, as a single dose, for most individuals 5 years of age and older. Children younger than 5 years may be eligible for additional doses of this season’s vaccine if they have not already received the three-dose series of COVID-19 vaccines, according to a company press release.

Pfizer Chairman and CEO Albert Bourla said: “This decision comes at a time when COVID-19 cases are on the rise again. Most people 6 months of age or older in the U.S. are now eligible for the COVID-19 vaccine this season, even if they have never been vaccinated against COVID-19 before. We expect this season’s vaccine to be available in the coming days, pending a recommendation from public health officials, so people can ask their doctor if it is possible to get the COVID-19 vaccine just as they do for the annual flu vaccine, which will save time and help prevent serious illness when respiratory viruses are at their peak.”

The company also announced yesterday that it is restarting production at its North Carolina plant, which was hit by a tornado in July of this year. With this good news, the company also warned that supplies of some drugs may not be fully restored until the middle of next year.

Pfizer is currently focusing on acquiring new companies to strengthen its pipeline of future products, such as the $5.4 billion buyout of Global Blood Therapeutics Inc and the $11.6 billion buyout of migraine drug maker Biohaven. Pfizer Inc (NYSE-PFE) also pays regular attractive quarterly dividends to its shareholders. The dividend yield is currently 4.97% p.a. The actual dividend amount has been approved by the company’s board of directors at $0.41 per share. These facts have attracted private investors and multinational investment corporations to buy shares of Pfizer Inc. (NYSE-PFE) in particular, for which the average target price for the short- to medium-term investment horizon has been set at USD 45.33 per share.

Vertex Pharmaceuticals (VRTX:NASDAQ) is an American biopharmaceutical company headquartered in Boston, Massachusetts. It was one of the first biotechnology companies to use an explicit strategy of rational drug design without chemistry. The company has three research facilities, in Sandiego, California, and in Milton Park and Oxfordshire, England. Vertex was founded in 1989 by Joshua Boger and Kevin J. Kinsella to “transform the way we treat serious diseases. Until 2004, the company focused primarily on viral infections, inflammatory, autoimmune diseases and cancer. In 2009, the company had about 1,800 employees. In 2019, there were about 2,500 employees. Since the end of 2011, Vertex has been ranked among the top 15 best performing companies in the Standard & Poor’s 500 . Vertex stock has increased 250% over the same period. In January 2014, Vertex completed its move from Cambridge, Massachusetts to Boston, Massachusetts, and settled into a new $800 million complex. This is located on the waterfront in South Boston. In June 2019, Vertex Pharmaceuticals (VRTX:NASDAQ) announced that it will acquire Exonics Therapeutics for $1 billion and partner with CRISPR Therapeutics to advance its development of treatments for Duchenne disease, a so-called muscular dystrophy, and myotonic dystrophy type 1.

Vertex Pharmaceuticals Incorporated(Nasdaq: VRTX) announced that the European Medicines Agency (CHMP) (Committee for Medicinal Products for Human Use ) has adopted a positive opinion on the approval of KAFTRIO ® , for the treatment of cystic fibrosis in children aged 2 to 5 years. The first of these medicines, KALYDECO ® (ivacaftor), was approved in 2012. A new drug, KAFTRIO ®, is currently approved for children aged 1 month and older.

Vertex researchers have also won a breakthrough prize for life science, among others. Chief Scientific Officer and Executive Vice President of Global Research David Altshuler, M.D., Ph.D. said “The research teams led by Paul, Fred and Sabine have discovered the first and only drug that addresses the underlying cause of cystic fibrosis. This remarkable effort required the discovery of three new mechanisms of action, leading to the first disease-modifying therapies that work by restoring the function of a misfolded protein.” “This award recognizes both the dedication and creativity of thousands of researchers, as well as the development, access to patients, and tireless staff who have worked to bring medicines to people with CF around the world.”

The company also recently reported financial results for the second quarter of 2023

 The second quarter of 2023 marked another period of significant progress for the business. Cystic fibrosis drugs are reaching more and more patients around the world than ever before. Vertex Pharmaceuticals (VRTX:NASDAQ) is also moving other programs with clinical trials into the final phase, making rapid progress in the development of additional drugs.

Tržby společnosti Vertex Pharmaceuticals (VRTX:NASDAQ) v porovnání se stejným čtvrtletím předchozího roku vzrostly o 14% na 2,49 miliardy USD. Společnost také zvýšila náklady na výzkum a vývoj z 877 milionu USD na 1,2 miliardy USD. Čistý zisk se meziročně zvýšil o 13% na především díky silnému růstu výnosů.

The domestic currency of the United Kingdom of Great Britain and Northern Ireland, the British pound (GBP), has so far not found support in the framework of forex operations of the foreign exchange market, according to economic correspondents linked to analysts of brokerage companies and financial strategists of the foreign exchange market. The exchange value of the British pound (GBP) against the US dollar (USD) is now still holding below the cross-rate level of 1.2600 USD per GBP, which financial strategists consider to be the so-called support point (support limit) of this GBP currency pair /USD.

Currently, during the European morning of this Wednesday, September 6, 2023, at approximately 7:35 CET, the exchange rate between the British pound (GBP) and the US dollar (ISD), as the world’s reserve currency, was at an exchange rate of 1.258 USD to EUR with the GBP strengthening by +0.11% against the USD on the day to date. This mutual exchange rate was achieved when the total exchange value of the US dollar, as measured by the US Dollar Currency Index (DXY), which compares the value of the USD to six other major world currencies, including the GBP, was at the point level of 104, 64 USD points with a daily decrease of -0.16% of the point value according to this index.

Thus, on the indicated day and time, the global currency pair of the single European currency euro (EUR) and the US dollar (USD) was traded on the foreign exchange market at the value of the mutual exchange rate of 1.073 USD per EUR with the daily strengthening of the EUR by + 0.12% of the rate so far against the USD. The British pound (GBP) nevertheless strengthened against the euro (EUR) in this situation, at a mutual exchange rate of 0.853 GBP per EUR, with the daily strengthening of the GBP by + 0.047% against the EUR. This strengthening of the British pound (GBP) both against the American dollar (USD), as the world’s main commodity currency, and against the single European currency, the euro (EUR), compared to its exchange value at the beginning of this 36th week of 2023, occurred according to analysts on the basis of relatively positive results on BRC retail sales data.

However, according to the statements of economic correspondents in connection with analysts of brokerage companies and financial strategists of investment banks in relation to the foreign exchange market, these positive data were still not enough for a strong enough investor sentiment that could swing the so-called exchange rate of the British pound (GBP) and the US dollar ( USD) at the mutual exchange rate limit above USD 1.2600 per GBP. Economic correspondents then tell the matter that while the retail sales figures were strong, the GBP has yet to find support in the markets due to the drop in China’s services PMI to its lowest level this year. The index’s 51.8 point is fast approaching the 50 median that separates expansion from the contracting services sector. Recent Chinese economic data supports this slowdown, and growth concerns continue to gain momentum. The Chinese government has since issued statements to stimulate the economy, but so far without major changes, markets remain cautious.